GO
Loading...

Amgen Inc

More

  • Final Glance: Biotechnology companies Friday, 19 Dec 2014 | 6:41 PM ET

    Amgen Inc. rose $1.69 or 1.0 percent, to $170.17. Biogen Idec rose $6.97 or 2.0 percent, to $360.67. Celgene Corp. rose$. 70 or. 6 percent, to $117.18.

  • Dec 19- AstraZeneca Plc's ovarian cancer drug has been granted an accelerated approval by the U.S. health regulator, a day after the treatment was approved by the European Commission. AstraZeneca expects potential sales of around $2 billion a year from the drug. London- based AstraZeneca's U.S.-listed shares were down about 1 percent at $71.41 in afternoon...

  • Midday Glance: Biotechnology companies Friday, 19 Dec 2014 | 1:25 PM ET

    Amgen Inc. rose$. 07 or percent, to $168.55. Biogen Idec rose $4.57 or 1.3 percent, to $358.27. Celgene Corp. rose$. 44 or. 4 percent, to $116.92.

  • Early Glance: Biotechnology companies Friday, 19 Dec 2014 | 10:20 AM ET

    Amgen Inc. fell$. 37 or. 2 percent, to $168.11. Biogen Idec fell $3.70 or 1.0 percent, to $350.00. Celgene Corp. rose$. 12 or. 1 percent, to $116.60.

  • Final Glance: Biotechnology companies Thursday, 18 Dec 2014 | 8:08 PM ET

    Amgen Inc. rose $5.00 or 3.1 percent, to $168.48. Biogen Idec rose $20.81 or 6.3 percent, to $353.70. Celgene Corp. rose $3.66 or 3.2 percent, to $116.48.

  • Midday Glance: Biotechnology companies Thursday, 18 Dec 2014 | 1:48 PM ET

    Amgen Inc. rose $3.32 or 2.0 percent, to $166.80. Biogen Idec rose $15.05 or 4.5 percent, to $347.94. Celgene Corp. rose $2.68 or 2.4 percent, to $115.50.

  • Early Glance: Biotechnology companies Thursday, 18 Dec 2014 | 11:11 AM ET

    Amgen Inc. rose $2.18 or 1.3 percent, to $165.66. Biogen Idec rose $12.84 or 3.9 percent, to $345.73. Celgene Corp. rose $2.63 or 2.3 percent, to $115.45.

  • Final Glance: Biotechnology companies Wednesday, 17 Dec 2014 | 7:08 PM ET

    Amgen Inc. rose $4.04 or 2.5 percent, to $163.48. Biogen Idec rose $7.76 or 2.4 percent, to $332.89. Celgene Corp. rose $2.73 or 2.5 percent, to $112.82.

  • Leaked Sony emails show Loeb influence on studio execs Wednesday, 17 Dec 2014 | 3:11 PM ET

    TOKYO/ BOSTON, Dec 17- Sony Corp movie executives kept up a dialogue with hedge fund titan Daniel Loeb, even after rebuffing the billionaire investor's proposal to sell up to one-fifth of the studio's entertainment business, leaked emails show. Loeb's New York- based Third Point took a 7 percent stake in the company in May 2013 and suggested that proceeds from a...

  • Midday Glance: Biotechnology companies Wednesday, 17 Dec 2014 | 1:17 PM ET

    Amgen Inc. rose $1.41 or. 9 percent, to $160.85. Biogen Idec rose $2.00 or. 6 percent, to $327.13. Celgene Corp. rose$. 63 or. 6 percent, to $110.72.

  • Dec 17- Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available on Thursday, which would make it one of the world's most expensive cancer drugs. "We believe the price reflects the significant clinical, economic and humanistic value of the product to patients and the healthcare system,...

  • EXCLUSIVE-Amgen leukemia drug to carry $178,000 price tag Wednesday, 17 Dec 2014 | 11:28 AM ET

    Dec 17- Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available this month, which would make it one of the world's most expensive cancer drugs. Company spokeswoman Danielle Bertrand said the price for the infused medicine, called Blincyto, would reflect two courses of treatment, at...

  • Early Glance: Biotechnology companies Wednesday, 17 Dec 2014 | 10:16 AM ET

    Amgen Inc. rose $1.19 or. 7 percent, to $160.63. Biogen Idec fell$. 02 or percent, to $325.11. Celgene Corp. rose$. 26 or. 2 percent, to $110.35.

  • Final Glance: Biotechnology companies Tuesday, 16 Dec 2014 | 6:41 PM ET

    Amgen Inc. fell$. 16 or. 1 percent, to $159.44. Biogen Idec fell $10.67 or 3.2 percent, to $325.13. Celgene Corp. fell $1.79 or 1.6 percent, to $110.09.

  • Midday Glance: Biotechnology companies Tuesday, 16 Dec 2014 | 1:20 PM ET

    Amgen Inc. rose $2.63 or 1.6 percent, to $162.23. Biogen Idec fell $2.99 or. 9 percent, to $332.81. Celgene Corp. rose$. 30 or. 3 percent, to $112.18.

  • Early Glance: Biotechnology companies Tuesday, 16 Dec 2014 | 10:20 AM ET

    Amgen Inc. rose$. 39 or. 2 percent, to $159.99. Biogen Idec rose$. 70 or. 2 percent, to $336.50. Celgene Corp. fell $1.53 or 1.4 percent, to $110.35.

  • Final Glance: Biotechnology companies Monday, 15 Dec 2014 | 6:08 PM ET

    Amgen Inc. fell $4.93 or 3.0 percent, to $159.60. Biogen Idec fell $8.69 or 2.5 percent, to $335.80. Celgene Corp. fell $2.61 or 2.3 percent, to $111.88.

  • Midday Glance: Biotechnology companies Monday, 15 Dec 2014 | 1:43 PM ET

    Amgen Inc. fell $3.39 or 2.1 percent, to $161.14. Biogen Idec fell $5.90 or 1.7 percent, to $338.59. Celgene Corp. fell $1.30 or 1.1 percent, to $113.19.

  • Early Glance: Biotechnology companies Monday, 15 Dec 2014 | 12:00 PM ET

    Amgen Inc. fell $1.94 or 1.2 percent, to $162.60. Biogen Idec fell$. 44 or. 1 percent, to $344.05. Celgene Corp. rose$. 47 or. 4 percent, to $114.96.

  • Final Glance: Biotechnology companies Friday, 12 Dec 2014 | 6:03 PM ET

    Amgen Inc. fell $1.55 or. 9 percent, to $164.53. Biogen Idec rose $2.16 or. 6 percent, to $344.49. Celgene Corp. fell $2.25 or 1.9 percent, to $114.49.